NasdaqCM:VRDNBiotechs
Viridian Therapeutics (VRDN) Valuation After Wider Q4 Loss And Ongoing Thyroid Eye Disease Regulatory Reviews
Viridian Therapeutics (VRDN) is in focus after reporting a larger than expected Q4 2025 loss and lower than forecast revenue. Its lead thyroid eye disease candidate remains under FDA Priority Review and EMA review.
See our latest analysis for Viridian Therapeutics.
At a share price of US$30.25, Viridian’s 1 day share price return of 2.96% and 7 day share price return of 7.77% follow a weaker 30 day share price return of an 8.33% decline. The 1 year total shareholder return of 109.92%...